ZINFORO® dosing in renal impairment1
| Header | ||
|---|---|---|
| Header | Header | Header |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
*Applies only for standard dose regimens in adults, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis).1
†Calculated using the Cockcroft-Gault formula.1
‡Dose is based on CrCl. CrCl should be closely monitored and the dose is adjusted according to the changing renal function.1
§Infusion times of <60 minutes and high-dose recommendations are based on PK/PD analyses only.1
ǁZINFORO® is haemodialysable. Therefore, it should be administered after haemodialysis on haemodialysis days.
¶For the treatment of S. aureus for which the ZINFORO® MIC is ≤1 mg/L, the standard dose is recommended.1
CAP, community-acquired pneumonia; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; ESRD, end-stage renal disease; PD, pharmacodynamics; PK, pharmacokinetics ; q8h, every 8 hours; q12h, every 12 hours.
Reference:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.